Pharmaceutical composition containing anti-VEGF fusion protein

By controlling the content of protein fragment B in the pharmaceutical composition, the problem of denaturation and polymerization of anti-VEGF fusion protein during preservation is solved, and the stability and biological activity of fusion protein A are improved.

CN120204358APending Publication Date: 2025-06-27CHENGDU KANGHONG BIOTECH CO LTD
2 Cites 0 Cited by

Patent Information

Application Number
CN202411947174.9
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2023-12-27
Filing Date
2024-12-27
Publication Date
2025-06-27

AI Technical Summary

Technical Problem

Anti-VEGF fusion proteins are susceptible to environmental factors during preservation and use, resulting in protein denaturation, polymerization and activity reduction, which in turn affects therapeutic effect and safety.

Method used

By controlling the content of low molecular weight protein fragment B in the pharmaceutical composition, especially in the range of 0.01 to 7%, the anti-VEGF fusion protein A is stabilized, and its stability and biological activity is improved.

Benefits of technology

It effectively reduces the polymerization rate of fusion protein A, improves its stability and biological activity, and maintains good activity even after high temperature treatment.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The invention provides a pharmaceutical composition containing an anti-VEGF (vascular endothelial growth factor) fusion protein. The pharmaceutical composition contains a protein of an anti-VEGF fusion protein A and a protein fragment B, by controlling the content of the protein fragment B in the pharmaceutical composition to be 0.01-7%, the polymerization rate of the protein in the composition can be reduced, the stability of the protein can be improved, good biological activity can be maintained, and the pharmaceutical composition has important significance for developing stable protein pharmaceutical preparations.
Need to check novelty before this filing date? Find Prior Art